Beans are a key food at the dietary level, boasting high nutritional value and constituting the most directly consumed legume ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

TD Cowen upgraded Crispr Therapeutics (CRSP) to Hold from Sell with an unchanged price target of $35. The firm continues to be cautious on the ...

Barclays analyst Gena Wang raised the firm’s price target on Crispr Therapeutics (CRSP) to $56 from $55 and keeps an Equal Weight rating on the ...

ZUG, Switzerland and BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical ...

CRISPR technology has radically transformed genetic research, and at the forefront of this transformation is CRISPR screening ...

Financial writer recommends Crispr Therapeutics AG as a strong buy due to cash position, drug pipeline, and promising ...

Gene editing promised a revolution, but biotech layoffs, stock slumps, and industry struggles reveal a stark reality: CRISPR ...

Zacks Research decreased their Q1 2025 EPS estimates for CRISPR Therapeutics in a report issued on Wednesday, February 5th. Zacks Research analyst R. Department now anticipates that the company will ...

CRISPR Gene editing therapy is used for the first time in living humans with amazing results.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

It’s a new way to create “bi-paternal” mice that can survive to adulthood—but human applications are still a long way off.